DRP-104 for Advanced Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Advanced Solid Tumors+7 MoreDRP-104 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying the safety and effectiveness of DRP-104 given by itself or with atezolizumab in treating patients with solid tumors that have spread to other parts of the body.

Eligible Conditions
  • Advanced Solid Tumors
  • Squamous Cell Carcinoma of the Head and Neck
  • Non-small Cell Lung Cancer (NSCLC), Recurrent
  • Non-Small Cell Lung Cancer Metastatic

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Part 2B Dose Expansion
1
LOXO-783
1
BGB-3245

Study Objectives

6 Primary · 8 Secondary · Reporting Duration: anticipated 2 year

anticipated 1 year
Area under the plasma concentration versus time curve (AUC)
Cmax of DRP-104
Maximum Tolerated Dose (MTD
Pharmacokinetics (PK) of DRP-104
anticipated 2 year
Disease control rate
Duration of response
Maximum Tolerated Dose (MTD)
Overall Response Rate
Overall survival (OS)
Progression-free survival
anticipated 2 years
Disease Control Rate (DCR)
Overall Response Rate (ORR)
Overall Survival (OS)
Progression-Free Survival (PFS)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Part 2B Dose Expansion
1
LOXO-783
1
BGB-3245

Trial Design

4 Treatment Groups

Part 2
1 of 4
Part 4
1 of 4
Part 3
1 of 4
Part 1a & Part 1b
1 of 4

Experimental Treatment

246 Total Participants · 4 Treatment Groups

Primary Treatment: DRP-104 · No Placebo Group · Phase 1 & 2

Part 2
Drug
Experimental Group · 1 Intervention: DRP-104 · Intervention Types: Drug
Part 4Experimental Group · 2 Interventions: atezolizumab, DRP-104 · Intervention Types: Biological, Drug
Part 3Experimental Group · 2 Interventions: atezolizumab, DRP-104 · Intervention Types: Biological, Drug
Part 1a & Part 1b
Drug
Experimental Group · 1 Intervention: DRP-104 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: anticipated 2 year

Who is running the clinical trial?

Dracen Pharmaceuticals, Inc.Lead Sponsor
Sunil Sharma, MDPrincipal InvestigatorHonorHealth Director
8 Previous Clinical Trials
133 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a measurable, advanced or recurrent, histologically or cytologically confirmed, measurable by RECIST 1.1 metastatic or unresectable solid tumor.
You have a performance status of 0 or 1.
Cardiac QTc (Fridericia) <470 ms.
You are a woman of child-bearing potential and you are sexually active.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top